Australien - engelsk - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone, quantity: 9 mg - tablet, modified release - excipient ingredients: sodium chloride; iron oxide red; purified water; hyetellose; macrogol 3350; carnauba wax; butylated hydroxytoluene; polyethylene oxide; povidone; stearic acid; isopropyl alcohol; propylene glycol; iron oxide black; hypromellose; titanium dioxide; macrogol 400; cellulose acetate - invega is indicated for the treatment of schizophrenia, including acute treatment and recurrence prevention. invega is indicated for the treatment of acute exacerbations of schizoaffective disorder as monotherapy and in combination with antidepressants and/or mood stabilizers (lithium and valproate).

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone, quantity: 6 mg - tablet, modified release - excipient ingredients: butylated hydroxytoluene; sodium chloride; povidone; stearic acid; polyethylene oxide; iron oxide red; hyetellose; macrogol 3350; macrogol 400; carnauba wax; isopropyl alcohol; propylene glycol; cellulose acetate; titanium dioxide; hypromellose; purified water; iron oxide black; iron oxide yellow - invega is indicated for the treatment of schizophrenia, including acute treatment and recurrence prevention. invega is indicated for the treatment of acute exacerbations of schizoaffective disorder as monotherapy and in combination with antidepressants and/or mood stabilizers (lithium and valproate).

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone, quantity: 3 mg - tablet, modified release - excipient ingredients: polyethylene oxide; iron oxide yellow; iron oxide red; butylated hydroxytoluene; purified water; carnauba wax; sodium chloride; hypromellose; iron oxide black; lactose monohydrate; triacetin; stearic acid; povidone; macrogol 3350; titanium dioxide; hyetellose; isopropyl alcohol; cellulose acetate; propylene glycol - invega is indicated for the treatment of schizophrenia, including acute treatment and recurrence prevention. invega is indicated for the treatment of acute exacerbations of schizoaffective disorder as monotherapy and in combination with antidepressants and/or mood stabilizers (lithium and valproate).

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - methylphenidate hydrochloride, quantity: 27 mg - tablet, modified release - excipient ingredients: cellulose acetate; polyethylene oxide; butylated hydroxytoluene; stearic acid; succinic acid; iron oxide red; poloxamer; carnauba wax; hypromellose; sodium chloride; phosphoric acid; povidone; iron oxide yellow; iron oxide black; titanium dioxide; lactose monohydrate; triacetin; macrogol 400; propylene glycol; isopropyl alcohol; purified water - concerta is indicated for the treatment of attention deficit hyperactivity disorder (adhd). treatment should be commenced by a specialist.,a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years.,need for comprehensive treatment programme concerta is indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician?s assessment of the chronicity and severity of the patient?s symptoms.,long term use the effectiveness of concerta for long-term use has not been systematically evaluated in controlled trials. therefore the physician who elects to use concerta for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - fentanyl, quantity: 2.1 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethylene/vinyl acetate copolymer; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative care, and other conditions in patients where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - fentanyl, quantity: 16.8 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethylene/vinyl acetate copolymer; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative care, and other conditions in patients where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - fentanyl, quantity: 12.6 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethylene/vinyl acetate copolymer; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative care, and other conditions in patients where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - fentanyl, quantity: 8.4 mg - drug delivery system, transdermal - excipient ingredients: ethylene/vinyl acetate copolymer; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative care, and other conditions in patients where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - fentanyl, quantity: 4.2 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethylene/vinyl acetate copolymer; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative care, and other conditions in patients where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - bortezomib, quantity: 3.5 mg - injection, powder for - excipient ingredients: mannitol; nitrogen - - velcade, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. - velcade, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. - velcade is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. - velcade in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.